Infection prophylaxis in antirheumatic therapy: Emphasis on vaccination

Current Opinion in Rheumatology

Volumn 21, Issue 4, 2009, Pages 419-424

  Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic agents; Immunosuppression; Rheumatoid arthritis; Vaccines

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLUENZA VACCINE; KEYHOLE LIMPET HEMOCYANIN; LIVE VACCINE; METHOTREXATE; PNEUMOCOCCUS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBODY RESPONSE; ANTIBODY TITER; AUTOIMMUNE DISEASE; DRUG MECHANISM; HUMAN; IMMUNITY; INFECTION; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; VACCINATION;

ANTIRHEUMATIC AGENTS; COMMUNICABLE DISEASES; DRUG INTERACTIONS; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION; RHEUMATIC DISEASES; VACCINES;

EID: 67149093549     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328329ec6e     Document Type: Review

References (26)

1. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls. Arthritis Rheum 2002; 46:2287-2293.
2. Hernandez-Cruz B, Cardiel MH, Villa AR, et al. Development, recurrence and severity of infection in Mexican patients with rheumatoid arthritis: a nested case-control study. J Rheumatol 1998; 25:1900-1907.
3. Crawford M, Curtis J. Tumor necrosis factor inhibitors and infectious complications. Curr Rheumatol Rep 2008; 10:383-389.
4. Saag KG, Teng GG, Patkar N, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762-784.
5. Furst DE, Keystone E, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67:iii2-iii25.
6. Kamchaisatian W, Wanwatsuntikul W, Sleasman JW, Tangsinmankong N. Validaton of current joint American Academy of Allergy, Asthma, and Immunology and American College of Allergy, Asthma, and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children. J Allergy Clin Immunol 2006; 118:1336-1341.
7. Glück T, Müller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Vaccines 2008; 46:1459-1465. An excellent review of responses to vaccinations among patients with rheumatic diseases and the effects of therapy.
8. Brezinschek H-P, Hofstaetter T, Leeb BF, et al. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. Curr Opin Rheumatol 2008; 20:295-299. An excellent review of recent published studies assessing responses to vaccinations, focusing on RA patients and treatment with TNF inhibitors.
9. Gelnick LBS, van der Bijl AE, Beyer WEP, et al. The effect of antitumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67:713-716. A detailed assessment of antibody responses to influenza vaccine and effect of antirheumatic therapy.
10. Gelnick LBS, van der Bijl AE, Visser LG, et al. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on the antibody responses to the 23 valent pneumococcal polysaccharide vaccine. Vaccine 2008; 26:3258-3333. A detailed assessment of antibody responses to pneumococcal vaccine and effect of antirheumatic therapy.
11. Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007; 11:1369-1384.
12. Moreland LW, Bucy RP, Weinblatt ME, et al. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002; 103:13-21.
13. Kavanaugh A, Greenwald M, Zizic T, et al. Immune response is not affected by adalimumab therapy. Ann Rheum Dis 2003; 62 (Suppl 1):169.
14. Tay L, Leon F, Vratsanos G, et al. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007; 9:R38.
15. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA-4IG mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103:1243-1252.
16. Gelinck LBS, Teng YKO, Rimmelzwaan GF, et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007; 66:1402-1403.
17. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67:937-941.
18. Bingham C, Looney R, Deodhar A, et al. Results from a controlled clinical trial (SIERRA) to evaluate primary and recall responses to immunizations in RA patients treated with rituximab. Arthritis Rheum 2008; 58:S900-S901 [abstract #1999].
19. Lder SA, Battafarano DF, Enzenauer RJ, Krieg AM. Can immunization precipitate connective tissue disease? Report of five cases and review of the literature. Semin Arthritis Rheum 1999; 29:131-139.
20. Conti F, Rezai S, Valesini G. Vaccination and rheumatic diseases: is there still a dilemma? Curr Rheumatol Rev 2007; 3:79-91.
21. A case of junk science, conflict and hype. Nat Immunol 2008; 9:1317.
22. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357:1903-1915. An interesting long-term intensive analysis of antibody responses in 45 persons for up to several decades defines the duration of antibody responses to common agents.
23. Cush J, Calabrese L, Kavanaugh A. ACR Hotline. Herpes zoster (Shingles) vaccine guidelines for immunosuppressed patients. http://www.rheumatology.org/ publications/hotline/. [Accessed 4 August 2008]
24. Johnstone J, Marrie TJ, Eurich DT, Majumdar SR. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia. Arch Intern Med 2007; 167:1938-1943. This study assesses outcomes among 3415 patients with community-acquired pneumonia in Canada from 2000 to 2002. The authors observed that there was a 40% lower mortality rate or ICU admission among persons who had had pneumococcal vaccination previously.
25. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:837-838.
26. Keitel WA, Atmar RL, Cate T, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-1127.